A Phase II Enrichment Study of Panitumumab as a Single Agent or in Combination With Trametinib in Cetuximab-Refractory Stage IV Colorectal Cancer Patients
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2018
At a glance
- Drugs Panitumumab (Primary) ; Trametinib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 02 Jan 2018 Planned End Date changed from 1 Apr 2022 to 1 Dec 2021.
- 02 Jan 2018 Planned primary completion date changed from 1 Apr 2022 to 1 Dec 2021.
- 02 Jan 2018 Status changed from not yet recruiting to recruiting.